Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: Potential relevance in diabetic retinopathy

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Ruiz, Michael Anthony ^a   Feng, Biao ^a   Chakrabarti, Subrata ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HISTONE H3; LYSINE; MICRORNA 200B; POLYCOMB REPRESSIVE COMPLEX 2; VASCULOTROPIN; MICRORNA; MIRN200 MICRORNA, HUMAN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY ENDOTHELIAL CELL; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENZYME INHIBITION; GENE REPRESSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERACTIONS WITH RNA; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; RETINA CELL; RETINAL ENDOTHELIAL CELL; RNA REPRESSION; ANIMAL; CELL LINE; DIABETES MELLITUS; DOWN REGULATION; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; METABOLISM; PATHOLOGY; RETINA; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

ANIMALIA;

ANIMALS; CELL LINE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLUCOSE; HUMANS; MALE; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; RATS, SPRAGUE-DAWLEY; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929484407     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123987     Document Type: Article

References (48)

1. Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW. How the diabetic eye loses vision. Endocrine. 2007; 32: 107-116. PMID: 17992608.
2. Chistiakov DA. Diabetic retinopathy: pathogenic mechanisms and current treatments. Diabetes Metab Syndr. 2011; 5: 165-172. doi:10.1016/j.dsx.2012.02.025 PMID: 22813573.
3. Chronopoulos A, Trudeau K, Roy S, Huang H, Vinores SA, Roy S. High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr Eye Res. 2011; 36: 747-753. doi:10.3109/02713683.2011.585735 PMID: 21780924.
4. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2002; 25: S28-s32.
5. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353: 2643-2653. PMID: 16371630.
6. Aiello LP, DCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014; 37: 17-23. doi:10.2337/dc13-2251 PMID: 24356593.
7. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994; 219: 713-725. PMID: 8112322.
8. Evans J, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress activated signaling pathways mediators of insulin resistance and beta cell dysfunction? Diabetes. 2003; 52: 1-8. PMID: 12502486.
9. Zourek M, Kyselová P, Mudra J, Krcma M, Jankovec Z, Lacigová S, et al. The relationship between glycemia, insulin and oxidative stress in hereditary hypertriglyceridemic rats. Physiol Res. 2008; 57: 531-538. PMID: 17705681.
10. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial. 2009; 13: 534-539. doi:10.1111/j.1744-9987.2009.00775.x PMID: 19954478.
11. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107: 1058-1070. doi:10.1161/CIRCRESAHA.110.223545 PMID: 21030723.
12. Son SM. Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. Diabetes Metab J. 2012; 36: 190-198. doi:10.4093/dmj.2012.36.3.190 PMID: 22737658.
13. Tousoulis D, Briasoulis A, Papageorgiou N, Tsioufis C, Tsiamis E, Toutouzas K, et al. Oxidative stress and endothelial function: Therapeutic interventions. Recent Pat. Cardiovasc. Drug Discov. 2011; 6: 103-114. PMID: 21513492.
14. Huang A, Yang YM, Yan C, Kaley G, Hintze TH, Sun D. Altered MAPK signaling in progressive deterioration of endothelial function in diabetic mice. Diabetes. 2012; 1: 3181-3188.
15. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011; 60: 1314-1323. doi:10.2337/db10-1557 PMID: 21357793.
16. Feng B, Chen S, McArthur K, Wu Y, Sen S, Ding Q, et al. miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes. 2011; 60: 2975-2984. doi:10.2337/db11-0478 PMID: 21885871.
17. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23: 4051-4060. PMID: 15372072.
18. Ma E, Zhou K, Kidwell MA, Doudna JA. Coordinated activities of human dicer domains in regulatory RNA processing. J Mol Biol. 2012; 422: 466-476. doi:10.1016/j.jmb.2012.06.009 PMID: 22727743.
19. Bushati N, Cohen SM. MicroRNA functions. Annu Rev Cell Dev Biol. 2007; 23: 175-205. PMID: 17506695.
20. Ruiz MA, Chakrabarti S. MicroRNAs: The underlying mediators of pathogenetic processes in vascular complications of diabetes. Can J Diabetes. 2013; 37: 339-344. doi:10.1016/j.jcjd.2013.07.003 PMID: 24500562.
21. Kumar M, Nath S, Prasad HK, Sharma GD, Li Y. MicroRNAs: A new ray of hope for diabetes mellitus. Protein Cell. 2012; 3: 726-738. doi:10.1007/s13238-012-2055-0 PMID: 23055040.
22. Schoof CR, Botelho EL, Izzotti A, Vasques Ldos R. MicroRNAs in cancer treatment and prognosis. Am J Cancer Res. 2012; 2: 414-433. PMID: 22860232.
23. Cheng X, Blumenthal RM. Coordinated chromatin control: Structural and functional linkage of DNA and histone methylation. Biochemistry. 2010; 49: 2999-3008. doi:10.1021/bi100213t PMID: 20210320.
24. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA. 2008 105: 9047-9052. doi:10.1073/pnas.0803623105 PMID: 18579779.
25. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009; 58:1229-1236. doi:10.2337/db08-1666 PMID: 19208907.
26. Syreeni A, El-Osta A, Forsblom C, Sandholm N, Parkkonen M, Tarnow L, et al. Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes. 2011; 60: 3073-3080. doi:10.2337/db11-0073 PMID: 21896933.
27. Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper ME, et al. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res. 2012; 110: 1067-1076. doi:10.1161/CIRCRESAHA.112.266171 PMID: 22403242.
28. Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol. 2013; 20: 1147-1155. doi:10.1038/nsmb.2669 PMID: 24096405.
29. Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE. EZH2: Biology, disease, and structure-based drug discovery. Acta Pharmacol Sin. 2014; 35: 161-174. doi:10.1038/aps.2013.161 PMID: 24362326.
30. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010; 18: 185-197. doi:10.1016/j.ccr.2010.06.016 PMID: 20708159.
31. Deb G, Thakur VS, Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics. 2013; 8: 464-476. doi:10.4161/epi.24532 PMID: 23644490.
32. Chadwick BP, Willard HF. SETting the stage. Eed-Enx1 leaves an epigenetic signature on the inactive X chromosome. Dev Cell. 2003; 4: 445-447. PMID: 12689584.
33. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell. 2004; 15: 57-67. PMID: 15225548.
34. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012; 106: 243-247. doi:10.1038/bjc.2011.551 PMID: 22187039.
35. Dreger H, Ludwig A, Weller A, Stangl V, Baumann G, Meiners S, et al. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells. Hypertension. 2012; 60: 1176-1183. doi:10.1161/HYPERTENSIONAHA.112.191098 PMID: 22966008.
36. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 2012; 56: 622-631. doi:10.1002/hep.25679 PMID: 22370893.
37. Feng B, Wang R, Chen LB. Review of MiR-200b and cancer chemosensitivity. Biomed Pharmacother. 2012; 66: 397-402. doi:10.1016/j.biopha.2012.06.002 PMID: 22795796.
38. Vrba L, Garbe JC, Stampfer MR, Futscher BW. Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res. 2011; 21: 2026-2037. doi:10.1101/gr.123935.111 PMID: 21873453.
39. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009; 8: 1579-1588. doi:10.1158/1535-7163.MCT-09-0013 PMID: 19509260.
40. Rudney H. The utilization of L-glucose bymammalian tissues and bacteria. Science. 1940; 92: 112-113. PMID: 17755265.
41. Yan J, Zhang Z, Shi H. HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells. Cell Mol Life Sci. 2012; 69: 115-128. doi:10.1007/s00018-011-0731-5 PMID: 21617913.
42. Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 2010; 17: 108.
43. Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li Y, et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLOS ONE. 2012; 7: e43726. doi:10.1371/journal.pone.0043726 PMID: 22952749.
44. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012; 72: 335-345. doi:10.1158/0008-5472.CAN-11-2182 PMID: 22108826.
45. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011; 30: 1956-1962 doi:10.1038/onc.2010.568 PMID: 21151178.
46. Kanhere A, Viiri K, Araújo CC, Rasaiyaah J, Bouwman RD, Whyte WA, et al. Short RNAs are transcribed from repressed polycomb target genes and interact with polycombrepressive complex-2. Mol Cell. 2010; 38: 675-688. doi:10.1016/j.molcel.2010.03.019 PMID: 20542000.
47. Ho L, Crabtree GR. An EZ mark to miss. Cell Stem Cell. 2008; 3: 577-578. doi:10.1016/j.stem.2008.11.007PMID: 19041770.
48. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev. 2004; 14: 155-164. PMID: 15196462.